The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The mutational landscape of lethal castration-resistant prostate cancer
Open accessAbstract
Characterization of the prostate cancer transcriptome and genome has identified chromosomal rearrangements and copy number gains and losses, including ETS gene family fusions, PTEN loss and androgen receptor (AR) amplification, which drive prostate cancer development and progression to lethal, metastatic castration-resistant prostate cancer (CRPC). However, less is known about the role of mutations. Here we sequenced the exomes of 50 lethal, heavily pre-treated metastatic CRPCs obtained at rapid autopsy (including three different foci from the same patient) and 11 treatment-naive, high-grade localized prostate cancers. We identified low overall mutation rates even in heavily treated CRPCs (2.00 per megabase) and confirmed the monoclonal origin of lethal CRPC. Integrating exome copy number analysis identified disruptions of CHD1 that define a subtype of ETS gene family fusion-negative prostate cancer. Similarly, we demonstrate that ETS2, which is deleted in approximately one-third of CRPCs (commonly through TMPRSS2:ERG fusions), is also deregulated through mutation. Furthermore, we identified recurrent mutations in multiple chromatin- and histone-modifying genes, including MLL2 (mutated in 8.6% of prostate cancers), and demonstrate interaction of the MLL complex with the AR, which is required for AR-mediated signalling. We also identified novel recurrent mutations in the AR collaborating factor FOXA1, which is mutated in 5 of 147 (3.4%) prostate cancers (both untreated localized prostate cancer and CRPC), and showed that mutated FOXA1 represses androgen signalling and increases tumour growth. Proteins that physically interact with the AR, such as the ERG gene fusion product, FOXA1, MLL2, UTX (also known as KDM6A) and ASXL1 were found to be mutated in CRPC. In summary, we describe the mutational landscape of a heavily treated metastatic cancer, identify novel mechanisms of AR signalling deregulated in prostate cancer, and prioritize candidates for future study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We and other groups have identified tumor alterations that reactivate AR signaling during treatment with an ARSI2,22–29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These mechanisms of resistance include AR gene amplification22,23, AR enhancer amplification2,24,25, AR mutation26, AR genomic structural rearrangements27, AR splice variants28 and polymorphisms in androgen metabolism genes29.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N. D., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E. G., Reva, B. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,713
The genomic complexity of primary human prostate cancer
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C. L., et al. (2011) · Nature · doi:10.1038/nature09744 · Cited by 1,232
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,046
Molecular genetics of prostate cancer: new prospects for old challengesPreprint
Shen, M. M., & Abate-Shen, C. T. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 991
FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
Lupien, M., Eeckhoute, J., Meyer, C. A., Wang, Q., Zhang, Y., Li, W., Carroll, J. S., Liu, X. S., & Brown, M. (2008) · Cell · doi:10.1016/j.cell.2008.01.018 · Cited by 983
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 897
Self-citationYu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.018 · Cited by 850
Self-citationWang, Q., Li, W., Liu, X. S., Carroll, J. S., Jänne, O. A., Keeton, E. K., Chinnaiyan, A. M., Pienta, K. J., & Brown, M. A. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.041 · Cited by 689
Self-citationGenome-wide analysis of ETS-family DNA-binding in vitro and in vivo
Wei, G., Badis, G., Berger, M. F., Kivioja, T., Palin, K., Enge, M., Bonke, M., Jolma, A., Varjosalo, M., Gehrke, A. R., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.106 · Cited by 568
Cited by
Sorted by citations
Items 601–700 of 1,005
FOXA1 mutations in hormone-dependent cancers
Robinson, J. L. L., Holmes, K. A., & Carroll, J. S. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00020 · Cited by 58
Pan-Cancer Analyses of the Nuclear Receptor Superfamily
Long, M. D., & Campbell, M. J. (2015) · Nuclear Receptor Research · doi:10.11131/2015/101182 · Cited by 56
Martin, P. L., Yin, J.-J., Seng, V., Casey, O. M., Corey, E., Morrissey, C. M., Simpson, R. M., & Kelly, K. (2016) · Oncogene · doi:10.1038/onc.2016.223 · Cited by 56
Aameri, R. F. H. A., Sheth, S., Alanisi, E. M. A., Borse, V., Mukherjea, D., Rybak, L. P., & Ramkumar, V. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177198 · Cited by 58
Samaranayake, G. J., Troccoli, C. I., Huynh, M. Q., Lyles, R. D. Z., Kage, K., Win, A., Lakshmanan, V., Kwon, D., Ban, Y. J., Chen, S. X., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01269-x · Cited by 56
González‐Chavarría, I., Fernandez, E. A., Gutiérrez, N., Gonzalez-Horta, E. E., Sandoval, F., Cifuentes, P., Castillo, C., Cerro, R. P., Sánchez, O., & Toledo, J. R. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.10.035 · Cited by 56
Molecular alterations and emerging targets in castration resistant prostate cancer
Lorente, D., & Bono, J. S. D. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.12.004 · Cited by 55
Xu, K., Wang, Z., Copland, J. A., Chakrabarti, R., & Florczyk, S. J. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120126 · Cited by 55
CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor
Wu, L., Runkle, C., Jin, H.-J., Yu, J., Li, J., Yang, X. J., Kuzel, T. M., Lee, C., & Yu, J. (2013) · Oncogene · doi:10.1038/onc.2012.602 · Cited by 55
A novel approach to identify driver genes involved in androgen-independent prostate cancer
Schinke, E. N., Bii, V. M., Nalla, A. K., Rae, D. T., Tedrick, L., Meadows, G. G., & Trobridge, G. D. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-120 · Cited by 56
Functional screen identifies kinases driving prostate cancer visceral and bone metastasis
Faltermeier, C. M., Drake, J. M., Clark, P. M., Smith, B. A., Zong, Y., Volpe, C., Mathis, C., Morrissey, C. M., Castor, B., Huang, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521674112 · Cited by 55
Downregulation of miR-195 promotes prostate cancer progression by targeting HMGA1
Zhang, X., Tao, T., Liu, C., Guan, H., Huang, Y., Xu, B., & Chen, M. (2016) · Oncology Reports · doi:10.3892/or.2016.4797 · Cited by 55
Albino, D., Civenni, G., Rossi, S., Mitra, A., Catapano, C. V., & Carbone, G. M. (2016) · Oncotarget · doi:10.18632/oncotarget.12525 · Cited by 55
Chen, M., Wan, L., Zhang, J., Zhang, J., Mendez, L., Clohessy, J. G., Berry, K., Victor, J., Yin, Q., Zhu, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02272-y · Cited by 61
KMT2D Mutation Is Associated With Poor Prognosis in Non–Small-Cell Lung Cancer
Ardeshir‐Larijani, F., Bhateja, P., Lipka, M. B., Sharma, N., Fu, P., & Dowlati, A. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.03.005 · Cited by 57
Wiesweg, M., Kasper, S., Worm, K., Herold, T., Reis, H., Sara, L., Metzenmacher, M., Abendroth, A., Darwiche, K., Aigner, C., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0634-0 · Cited by 55
Cytoreductive treatment strategies for de novo metastatic prostate cancer
Connor, M. J., Shah, T. T., Horan, G., Bevan, C. L., Winkler, M. H., & Ahmed, H. U. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0284-3 · Cited by 56
The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
Chakraborty, G., Nandakumar, S., Hirani, R., Nguyen, B., Stopsack, K. H., Kreitzer, C. K., Rajanala, S. H., Ghale, R., Mazzu, Y. Z., Pillarsetty, N., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4272 · Cited by 54
ASXL1/2 mutations and myeloid malignancies
Medina, E. A., Delma, C. R., & Yang, F. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01336-x · Cited by 55
Han, D. G., Labaf, M., Zhao, Y., Owiredu, J. N., Zhang, S., Patel, K. J., Venkataramani, K., Steinfeld, J. S., Han, W., Li, M., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci168649 · Cited by 56
Low‐grade prostate cancer diverges early from high grade and metastatic disease
VanderWeele, D. J., Brown, C. D., Taxy, J. B., Gillard, M., Hatcher, D. M., Tom, W. R., Stadler, W. M., & White, K. P. (2014) · Cancer Science · doi:10.1111/cas.12460 · Cited by 54
FOXA1 defines cancer cell specificity
Zhang, G., Zhao, Y., Liu, Y., Kao, L., Wang, X., Skerry, B., & Li, Z. (2016) · Science Advances · doi:10.1126/sciadv.1501473 · Cited by 54
Lee, A. R., Gan, Y., Tang, Y., & Dong, X. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.011 · Cited by 54
Lv, S., Wen, H., Shan, X.-W., Li, J., Wu, Y., Yu, X., Huang, W., & Wei, Q. (2019) · Epigenetics · doi:10.1080/15592294.2019.1634985 · Cited by 54
Self-citationEPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells
Sagar, V., Vatapalli, R. J., Lysy, B., Pamarthy, S., Anker, J. F., Rodríguez, Y., Han, H., Unno, K., Stadler, W. M., Catàlona, W. J., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2042-y · Cited by 54
Identification of key pathways and genes in PTEN mutation prostate cancer by bioinformatics analysis
Sun, J. M., Li, S., Wang, F., Fan, C., & Wang, J. (2019) · BMC Medical Genetics · doi:10.1186/s12881-019-0923-7 · Cited by 57
He, L., Fang, H., Chen, C., Wu, Y., Wang, Y., Ge, H., Wang, L., Wan, Y., & He, H. (2020) · Medicine · doi:10.1097/md.0000000000019760 · Cited by 55
Self-citationLeibold, J., Ruscetti, M. A., Cao, Z., Ho, Y.-J., Baslan, T., Zou, M., Abida, W. M., Feucht, J., Han, T., Barriga, F. M., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1242 · Cited by 56
The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape
Wang, L.-H., Aberin, M. A. E., Wu, S., & Wang, S.-P. (2021) · Biochemical Society Transactions · doi:10.1042/bst20191164 · Cited by 53
Maeda, S., Motegi, T., Iio, A., Kaji, K., Goto‐Koshino, Y., Eto, S., Ikeda, N., Nakagawa, T., Nishimura, R., Yonezawa, T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003731 · Cited by 55
An Update on Synthesis of Coumarin Sulfonamides as Enzyme Inhibitors and Anticancer Agents
Rubab, L., Afroz, S., Ahmad, S., Hussain, S., Nawaz, I., Irfan, A., Batool, F., Kotwica-Mojzych, K., & Mojzych, M. (2022) · Molecules · doi:10.3390/molecules27051604 · Cited by 53
Whitburn, J., Rao, S. R., Morris, E. V., Tabata, S., Hirayama, A., Soga, T., Edwards, J., Kaya, Z., Palmer, C., Hamdy, F. C., et al. (2022) · Science Advances · doi:10.1126/sciadv.abf9096 · Cited by 53
The application of 3D bioprinting in urological diseases
Xu, K., Han, Y., Huang, Y., Wei, P., Yin, J., & Jiang, J. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100388 · Cited by 54
You, L., Yan, K., Zhou, J., Hong, Z., Bertos, N., Park, M., Wang, E., & Yang, X. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005034 · Cited by 53
AR-Regulated TWEAK-FN14 Pathway Promotes Prostate Cancer Bone Metastasis
Yin, J., Liu, Y., Tillman, H. S., Barrett, B., Hewitt, S. M., Ylaya, K., Fang, L., Lake, R. G., Corey, E., Morrissey, C. M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3233 · Cited by 53
Genetic Progression of High Grade Prostatic Intraepithelial Neoplasia to Prostate Cancer
Jung, S., Shin, S. Y., Kim, M. S., Baek, I.-P., Lee, J. Y., Lee, S. H., Kim, T., Lee, S. H., & Chung, Y. (2015) · European Urology · doi:10.1016/j.eururo.2015.10.031 · Cited by 53
BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion
Blee, A. M., Liu, S., Wang, L., & Huang, H. (2016) · Oncotarget · doi:10.18632/oncotarget.9513 · Cited by 54
Stoyanova, T. I., Riedinger, M., Lin, S., Faltermeier, C. M., Smith, B. A., Zhang, K. X., Going, C. C., Goldstein, A. S., Lee, J. K., Drake, J. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614529113 · Cited by 54
Self-citationMunkley, J., McClurg, U. L., Livermore, K. E., Ehrmann, I. E., Knight, B., McCullagh, P. J., McGrath, J. S., Crundwell, M. C., Harries, L. W., Leung, H. Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05489-5 · Cited by 53
The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer
Mandel, A., Larsson, P., Sarwar, M., Semenas, J., Khaja, A. S. S., & Persson, J. L. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0035-4 · Cited by 53
Wu, R., Young, I.-C., Chen, Y.-F., Chuang, S.-T., Toubaji, A., & Wu, M. (2019) · Nature Communications · doi:10.1038/s41467-019-12184-8 · Cited by 53
Takayama, K., Fujimura, T., Suzuki, Y., & Inoue, S. (2020) · Communications Biology · doi:10.1038/s42003-020-01120-y · Cited by 54
Clinical and genomic features of SPOP‐mutant prostate cancer
Nakazawa, M., Fang, M., Marshall, C. H., Lotan, T. L., Velho, P. I., & Antonarakis, E. S. (2021) · The Prostate · doi:10.1002/pros.24269 · Cited by 55
Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical ImplicationsPreprint
Yegnasubramanian, S., Marzo, A. M. D., & Nelson, W. G. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030445 · Cited by 53
Development of Prostate Cancer Organoid Culture Models in Basic Medicine and Translational Research
Elbadawy, M., Abugomaa, A., Yamawaki, H., Usui, T., & Sasaki, K. (2020) · Cancers · doi:10.3390/cancers12040777 · Cited by 54
Modifying Adaptive Therapy to Enhance Competitive Suppression
Hansen, E., & Read, A. F. (2020) · Cancers · doi:10.3390/cancers12123556 · Cited by 52
Fernandes, R. C., Toubia, J., Townley, S. L., Hanson, A. R., Dredge, B. K., Pillman, K. A., Bert, A. G., Winter, J. M., Iggo, R. D., Das, R., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108585 · Cited by 52
AMPK activation protects against prostate cancer by inducing a catabolic cellular state
Penfold, L., Woods, A., Pollard, A., Arizanova, J., Pascual-Navarro, E., Muckett, P. J., Dore, M. H., Montoya, A., Whilding, C., Fets, L., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112396 · Cited by 54
The role and mechanism of NAT10‐mediated ac4C modification in tumor development and progression
Gu, Z., Zou, L., Pan, X., Yu, Y., Liu, Y., Zhang, Z., Liu, J., Mao, S., Zhang, J., Guo, C., et al. (2024) · MedComm · doi:10.1002/mco2.70026 · Cited by 52
Barakat, D. J., Zhang, J., Barberi, T., Denmeade, S. R., Friedman, A. D., & Paz‐Priel, I. (2015) · Oncogene · doi:10.1038/onc.2015.41 · Cited by 52
Molecular subtyping of prostate cancer
Kaffenberger, S. D., & Barbieri, C. E. (2016) · Current Opinion in Urology · doi:10.1097/mou.0000000000000285 · Cited by 52
Butt, N. A., Kumar, A., Dhar, S., Rimando, A. M., Akhtar, I., Hancock, J. C., Lage, J. M., Pound, C. R., Lewin, J. R., Gómez, C. R., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1209 · Cited by 52
Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers
Guo, T., Li, L., Zhong, Q., Rupp, N. J., Charmpi, K., Wong, C. E., Wagner, U., Rueschoff, J. H., Jochum, W., Fankhauser, C. D., et al. (2018) · Life Science Alliance · doi:10.26508/lsa.201800042 · Cited by 52
Feutren, T., & Herrera, F. G. (2018) · Prostate International · doi:10.1016/j.prnil.2018.03.005 · Cited by 52
Kounatidou, E. E., Nakjang, S., McCracken, S. R., Dehm, S. M., Robson, C. N., Jones, D. L., & Gaughan, L. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz286 · Cited by 52
Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic EraPreprint
Arriaga, J. M., & Abate-Shen, C. T. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030528 · Cited by 56
Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress
Liao, Y., Chen, C.-H., Xiao, T., Avalos, B. D. L. P., Dray, E. V., Cai, C., Gao, S., Shah, N., Zhang, Z., Feit, A. S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105898119 · Cited by 52
Overview on Biological Activities of Imidazole Derivatives
Gujjarappa, R., Kabi, A. K., Sravani, S., Garg, A., Vodnala, N., Tyagi, U., Kaldhi, D., Ravichandiran, V., Singh, V., Gupta, S., et al. (2022) · Materials horizons · doi:10.1007/978-981-16-8399-2_6 · Cited by 51
Matsubara, N., Bono, J. S. D., Olmos, D., Procopio, G., Kawakami, S., Ürün, Y., van Alphen, R., Fléchon, A., Carducci, M. A., Choi, Y. D., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3577 · Cited by 51
Unal, B., Kuzu, O. F., Jin, Y., Osorio, D., Kildal, W., Pradhan, M., Kung, S. H. Y., Oo, H. Z., Daugaard, M., Vendelbo, M. H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53039-1 · Cited by 53
MAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy
Zhang, X., Ma, L., Qi, J., Shan, H., Yu, W., & Gu, Y. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2542-8 · Cited by 53
DeGraff, D. J., Grabowska, M. M., Case, T. C., Yu, X., Herrick, M. K., Hayward, W. J., Strand, D. W., Cates, J., Hayward, S. W., Gao, N., et al. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.64 · Cited by 51
Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells
Lee, E., Ha, S., & Logan, S. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141589 · Cited by 52
Long noncoding RNAs in prostate cancer: overview and clinical implications
Feng, F., & Malik, B. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.177123 · Cited by 52
The role of peroxisome proliferator-activated receptor gamma in prostate cancer
Jones, J., Elix, C. C., & Pal, S. (2017) · Asian Journal of Andrology · doi:10.4103/aja.aja_15_17 · Cited by 51
The FOXO’s Advantages of Being a Family: Considerations on Function and Evolution
Schmitt-Ney, M. (2020) · Cells · doi:10.3390/cells9030787 · Cited by 55
New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
Conteduca, V., Mosca, A., Brighi, N., Giorgi, U. D., & Rescigno, P. (2021) · Cells · doi:10.3390/cells10010193 · Cited by 52
New Strategies in Prostate Cancer: Translating Genomics into the Clinic
Beltran, H., & Rubin, M. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1452 · Cited by 50
NRMT2 is an N-terminal monomethylase that primes for its homologue NRMT1
Petkowski, J. J., Bonsignore, L. A., Tooley, J. G., Wilkey, D. W., Merchant, M. L., Macara, I. G., & Tooley, C. E. S. (2013) · Biochemical Journal · doi:10.1042/bj20131163 · Cited by 50
Disruption of Prostate Epithelial Differentiation Pathways and Prostate Cancer Development
Frank, S. B., & Miranti, C. K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00273 · Cited by 53
TMPRSS2–ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c
Kim, J., Wu, L., Zhao, J. C., Jin, H.-J., & Yu, J. (2013) · Oncogene · doi:10.1038/onc.2013.461 · Cited by 50
Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC)
Udager, A. M., Alva, A. S., Chen, Y., Siddiqui, J., Lagstein, A., Tickoo, S. K., Reuter, V. E., Chinnaiyan, A. M., & Mehra, R. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000127 · Cited by 51
Self-citationFu, W., Tao, T., Qi, M., Wang, L., Hu, J., Li, X., Xing, N., Du, R., & Han, B. (2016) · The Prostate · doi:10.1002/pros.23241 · Cited by 50
Roussel-Gervais, A., Naciri, I., Kirsh, O., Kasprzyk, L., Velasco, G., Grillo, G., Dubus, P. R., & Defossez, P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1181 · Cited by 55
Integrative analysis of cancer driver genes in prostate adenocarcinoma
Zhao, X., Lei, Y., Li, G., Cheng, Y., Yang, H., Xie, L., Long, H., & Jiang, R. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9902 · Cited by 50
A Synthetic Overview of Benzoxazines and Benzoxazepines as Anticancer Agents
Chatterjee, I., Ali, K., & Panda, G. (2023) · ChemMedChem · doi:10.1002/cmdc.202200617 · Cited by 49
STAT5A/B Gene Locus Undergoes Amplification during Human Prostate Cancer Progression
Haddad, B. R., Gu, L., Mirtti, T. K., Dagvadorj, A., Vogiatzi, P., Hoang, D. T., Bajaj, R., Leiby, B. E., Ellsworth, E., Blackmon, S. M., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.02.044 · Cited by 51
Expression and role of PAICS, a de novo purine biosynthetic gene in prostate cancer
Chakravarthi, B. V. S. K., Goswami, M. T., Pathi, S. S., Dodson, M. B., Chandrashekar, D. S., Agarwal, S., Nepal, S., Balasubramanya, S. A. H., Siddiqui, J., Lonigro, R. J., et al. (2018) · The Prostate · doi:10.1002/pros.23533 · Cited by 49
Self-citationRosa, J. D. L., Weber, J., Friedrich, M., Li, Y., Rad, L., Ponstingl, H., Liang, Q., Fernández, S. B. D. Q., Noorani, I., Metzakopian, E., et al. (2017) · Nature Genetics · doi:10.1038/ng.3817 · Cited by 50
Prostatic cancers: understanding their molecular pathology and the 2016 WHO classification
Inamura, K. (2018) · Oncotarget · doi:10.18632/oncotarget.24515 · Cited by 51
Androgen receptor and soy isoflavones in prostate cancer (Review)
Sivoňov�, M., Kapl�n, P., Tatarkov�, Z., Lichardusov�, L., Dusenka, R., & Jurečekov�, J. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1792 · Cited by 49
Wu, L., Yi, B., Wei, S., Rao, D., He, Y., Naik, G., Bae, S., Liu, M., Yang, W., Sonpavde, G., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2049 · Cited by 49
Clonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma
Laudato, S., Aparicio, A. M., & Giancotti, F. G. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.05.008 · Cited by 50
CTCF loss mediates unique DNA hypermethylation landscapes in human cancers
Damaschke, N., Gawdzik, J. C., Avilla, M. N., Yang, B., Svaren, J. P., Roopra, A., Luo, J., Yu, Y. P., Keleş, S., & Jarrard, D. F. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00869-7 · Cited by 51
Xu, F., Shangguan, X., Pan, J., Yue, Z., Shen, K., Ji, Y., Zhang, W., Zhu, Y., Sha, J., Wang, Y., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33494 · Cited by 49
Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer
Liu, Z., Wang, P., Wold, E. A., Song, Q., Zhao, C., Wang, C., & Zhou, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01799 · Cited by 50
HMGB1: A Promising Therapeutic Target for Prostate Cancer
Munirathinam, G., Kalyanasundaram, R., Zheng, G., Chen, A., Bosland, M. C., & Kajdacsy‐Balla, A. (2013) · Prostate Cancer · doi:10.1155/2013/157103 · Cited by 49
Yue, X., Zhang, C., Zhao, Y., Liu, J., Lin, A. W., Tan, V. M., Drake, J. M., Liu, L., Boateng, M. N., Li, J., et al. (2017) · Genes & Development · doi:10.1101/gad.301564.117 · Cited by 50
Shangguan, X., Ma, Z., Yu, M., Ding, J., Xue, W., & Qi, J. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3822 · Cited by 48
Chen, L., Qian, Y., Jia, Q., Weng, R., Zhang, X., Li, Y., & Qiu, J. Y. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.160637 · Cited by 50
Comparative Genomic and Transcriptomic Analyses of LNCaP and C4-2B Prostate Cancer Cell Lines
Spans, L., Helsen, C., Clinckemalie, L., den Broeck, T. V., Preković, S., Joniau, S., Lerut, E., & Claessens, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090002 · Cited by 48
Lǚ, K., Liu, C., Tao, T., Zhang, X., Zhang, L., Sun, C., Wang, Y., Chen, S., Xu, B., & Chen, M. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.04.037 · Cited by 48
Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer
García-Flores, M., Casanova‐Salas, I., Rubio‐Briones, J., Calatrava, A. M., Dominguez-Escrig, J. L., Rubio, L., Backhaus, M., Fernández‐Serra, A., García‐Casado, Z., & López‐Guerrero, J. A. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.08.009 · Cited by 48
Sunkel, B. D., Wu, D., Chen, Z., Wang, C., Liu, X., Ye, Z., Horning, A. M., Liu, J., Mahalingam, D., Lopez-Nicora, H. D., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1528 · Cited by 48
Regulation of PCGEM1 by p54/nrb in prostate cancer
Ho, T.-T., Huang, J., Zhou, N., Zhang, Z., Koirala, P., Zhou, X., Wu, F., Ding, X., & Mo, Y. (2016) · Scientific Reports · doi:10.1038/srep34529 · Cited by 49
Hypoxia regulates ANXA1 expression to support prostate cancer cell invasion and aggressiveness
Bizzarro, V., Belvedere, R., Migliaro, V., Romano, E., Parente, L., & Petrella, A. (2016) · Cell Adhesion & Migration · doi:10.1080/19336918.2016.1259056 · Cited by 48
Role of steroid receptor and coregulator mutations in hormone-dependent cancers
Groner, A. C., & Brown, M. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88885 · Cited by 49
Abudureheman, A., Ainiwaer, J., Hou, Z., Niyaz, M., Turghun, A., Hasim, A., Zhang, H., Lu, X., & Sheyhidin, I. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2625-5 · Cited by 50
The PHLPP2 phosphatase is a druggable driver of prostate cancer progression
Nowak, D. G., Cohen‐Katsenelson, K., Watrud, K. E., Chen, M., Mathew, G., D’Andrea, V. D., Lee, M. F., Swamynathan, M. M., Casanova‐Salas, I., Jibilian, M. C., et al. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201902048 · Cited by 49
Androgen Receptor in Breast Cancer: From Bench to Bedside
Chen, M., Yang, Y., Xu, K., Li, L., Huang, J., & Qiu, F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00573 · Cited by 49
Metadata
- Authors
- Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., Asangani, I. A., Ateeq, B., Chun, S. Y., Siddiqui, J., Sam, L., Anstett, M., Mehra, R., Prensner, J. R., Palanisamy, N., Ryslik, G. A., Vandin, F., Raphael, B. J., Kunju, L. P., Rhodes, D. R., Pienta, K. J., Chinnaiyan, A. M., & Tomlins, S. A.
- Affiliations
- University of Michigan (US)
- Howard Hughes Medical Institute (US)
- Yale University (US)
- Brown University (US)
- Corresponding author
- Pienta, Kenneth J.
- Chinnaiyan, Arul M.
- ORCID
- Grasso, Catherine S.
- Robinson, Dan R.
- Cao, Xuhong
- Dhanasekaran, Saravana M.
- Khan, Amjad P.
- Jing, Xiaojun
- Brenner, J. Chad
- Asangani, Irfan A.
- Ateeq, Bushra
- Siddiqui, Javed
- Mehra, Rohit
- Prensner, John R.
- Palanisamy, Nallasivam
- Ryslik, Gregory A.
- Vandin, Fabio
- Raphael, Benjamin J.
- Kunju, Lakshmi P.
- Rhodes, Daniel R.
- Pienta, Kenneth J.
- Chinnaiyan, Arul M.
- Tomlins, Scott A.
- Venue
- Nature
- Published
- 2012-05-20
- Volume
- 487
- Issue
- 7406
- Pages
- 239-243
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3396711
- OpenAlex
- W2051025382
- Cited by
- 2,517
- References
- 23
- Citations by year
- 2026: 75 · 2025: 128 · 2024: 136 · 2023: 181 · 2022: 178 · 2021: 199 · 2020: 233 · 2019: 193 · 2018: 205 · 2017: 195 · 2016: 194 · 2015: 212 · 2014: 177 · 2013: 169 · 2012: 33
- FWCI
- 152.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (5r01ca013287-14)
- National Cancer Institute (P50-CA-69568, R01CA132874, U01CA111275, R01CA13287, P50CA069568, T32CA140044, P30CA046592, T32CA009676, U01CA113913)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- castration-resistant prostate cancer, metastatic prostate cancer, somatic mutations, copy number alterations, chromatin modifiers, androgen receptor, FOXA1, KMT2D, TMPRSS2-ERG fusion, PTEN loss, androgen receptor amplification, chromosomal rearrangements
- MeSH terms
- Cells, Cultured, Humans, Male, Molecular Sequence Data, Mutation, Orchiectomy, Prostatic Neoplasms, Receptors, Androgen, Signal Transduction, Sequence Alignment, Cell Proliferation, Hepatocyte Nuclear Factor 3-alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
